Limbal Stem Cell — IND submission
2026
This paves the way for us to submit Investigational New Drug (IND) applications to the FDA for both Dry Eye Disease and Age-Related Macular Degeneration in 2026.Source filing
YDES biotech catalysts & pipeline
YD BIO LTD · Data as of 2026-09-08